Abstract
A large body of evidence point out that the onset of synthetic lethality may provide a useful tool for amplifying the efficacy of drugs in anticancer regimens, to uncover interdependence between genes and to identify predictive factors that would be extremely useful to guide in the selection of more effective targeted drugs and drug combinations for each patient. Here, we provide an overview on the exploitation of synthetic lethality to overcome drug resistance to conventional chemotherapy in several types of solid tumors. We report recent findings on cellular markers and gene mutations which are specifically essential for the viability of cancer cells and for resistance to chemotherapeutics. In addition, new molecularly targeted strategies to overcome drug resistance are suggested.
Keywords: Synthetic lethality, drug resistance, solid tumors, PARP inhibitors, DNA repair pathway, anticancer therapy, anticancer regimens, genes, cellular markers, cancer cells
Current Medicinal Chemistry
Title:Synthetic Lethality to Overcome Cancer Drug Resistance
Volume: 19 Issue: 23
Author(s): L. Porcelli, A. E. Quatrale, P. Mantuano, N. Silvestris, A. E. Brunetti, H. Calvert, A. Paradiso and A. Azzariti
Affiliation:
Keywords: Synthetic lethality, drug resistance, solid tumors, PARP inhibitors, DNA repair pathway, anticancer therapy, anticancer regimens, genes, cellular markers, cancer cells
Abstract: A large body of evidence point out that the onset of synthetic lethality may provide a useful tool for amplifying the efficacy of drugs in anticancer regimens, to uncover interdependence between genes and to identify predictive factors that would be extremely useful to guide in the selection of more effective targeted drugs and drug combinations for each patient. Here, we provide an overview on the exploitation of synthetic lethality to overcome drug resistance to conventional chemotherapy in several types of solid tumors. We report recent findings on cellular markers and gene mutations which are specifically essential for the viability of cancer cells and for resistance to chemotherapeutics. In addition, new molecularly targeted strategies to overcome drug resistance are suggested.
Export Options
About this article
Cite this article as:
Porcelli L., E. Quatrale A., Mantuano P., Silvestris N., E. Brunetti A., Calvert H., Paradiso A. and Azzariti A., Synthetic Lethality to Overcome Cancer Drug Resistance, Current Medicinal Chemistry 2012; 19 (23) . https://dx.doi.org/10.2174/092986712802002563
DOI https://dx.doi.org/10.2174/092986712802002563 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
![](/images/wayfinder.jpg)
- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Meet Our Editorial Board Member
Current Gene Therapy Cancer-Type Organic Anion Transporting Polypeptide 1B3: Current Knowledge of the Gene Structure, Expression Profile, Functional Implications and Future Perspectives
Current Drug Metabolism The Interplay Between Inflammation and Oxidative Stress in Carcinogenesis
Current Molecular Medicine Development of Long-Circulating and Fusogenic Liposomes Co-encapsulating Paclitaxel and Doxorubicin in Synergistic Ratio for the Treatment of Breast Cancer
Current Drug Delivery Summary of Information on the Effects of Ionizing and Non-ionizing Radiation on Cytochrome P450 and Other Drug Metabolizing Enzymes and Transporters
Current Drug Metabolism ImmunoPET in Neoplasms of Gastrointestinal Tract, Liver and Pancreas in the XXIst Century: Bridging the Gap Between Diagnosis and Therapy
Reviews on Recent Clinical Trials Cancer Stem Cells and their Management in Cancer Therapy
Recent Patents on Anti-Cancer Drug Discovery The Emerging Role of Vascular Endothelial Growth Factor (VEGF) in Vascular Homeostasis: Lessons from Recent Trials with Anti-VEGF Drugs
Current Vascular Pharmacology Cucurbitacins as Inducers of Cell Death and a Rich Source of Potential Anticancer Compounds
Current Pharmaceutical Design Oncologists Current Opinion on the Treatment of Colon Carcinoma
Anti-Cancer Agents in Medicinal Chemistry Targeting Heat Shock Proteins in Tauopathies
Current Alzheimer Research A Review on Onychine and its Analogs: Synthesis and Biological Activity
Current Organic Synthesis Reactive Oxygen Species in Cancer Biology and Anticancer Therapy
Current Medicinal Chemistry Risk Factors for Prolonged Postoperative Ileus in Adult Patients Undergoing Elective Colorectal Surgery: An Observational Cohort Study
Reviews on Recent Clinical Trials Functional Nanoplatforms for Enhancement of Chemotherapeutic Index
Anti-Cancer Agents in Medicinal Chemistry CDK12 Promotes Breast Cancer Progression and Maintains Stemness by Activating c-myc/β -catenin Signaling
Current Cancer Drug Targets Human Amniotic Fluid Stem Cells as an Attractive Tool for Clinical Applications
Current Stem Cell Research & Therapy Biomedical Applications of Superparamagnetic Nanoparticles in Molecular Scale
Current Organic Chemistry Meet Our Editorial Board Member:
Current Drug Targets Pharmacokinetics-Pharmacology Disconnection of Herbal Medicines and its Potential Solutions with Cellular Pharmacokinetic-Pharmacodynamic Strategy
Current Drug Metabolism